Bristol-Myers Squibb (BMY) Tops Q2 EPS by 15c, Updates FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Bristol Myers Squibb Reports Second Quarter 2020 Financial Results
August 6, 2020 6:59 AM EDTReports Second Quarter Revenues of $10.1 Billion Posts GAAP Loss Per Share of $0.04 and Non-GAAP EPS of $1.63 Advances Pipeline with Positive Topline Results for Zeposia in Ulcerative Colitis; Approvals for Opdivo plus Yervoy in Lung Cancer Updates 2020 GAAP EPS Guidance Range from $0.37-$0.57 to ($0.06)-$0.09 and Non-GAAP EPS Guidance Range from $6.00-$6.20 to $6.10-$6.25
NEW YORK--(BUSINESS... More
